Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Gemini Space Station Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.76 (market cap $8.04B), while Gemini Space Station Inc trades at $4.59 (market cap $548.72M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 14.7× Gemini Space Station Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| BIO | GEMI | |
|---|---|---|
Market Cap | $8.04B | $548.72M |
Sector | Health | Technology |
52-Week High | $339.75 | $32.52 |
52-Week Low | $241.71 | $3.91 |
Enterprise Value | $7.85B | $538.70M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
GEMI trades at $4.25, down 1.39% on the day, amid a bearish technical signal and weak fundamentals. The company reported significant losses, with a net income margin of -278.9% in 2025, and has missed earnings expectations for three consecutive quarters. Recent news includes a class action lawsuit and a $100 million investment from Winklevoss Capital, creating mixed sentiment.
The outlook remains challenging due to persistent unprofitability and legal risks, though analyst consensus suggests moderate upside with a $5.88 price target. Investment opportunity hinges on the company's ability to leverage new capital for growth, but high execution and regulatory risks warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
